Clinician Perspectives on Overactive Bladder Management: A Focus on Mirabegron Prescribing Practices in India

Abstract

Objective: The survey aims to gather clinicians’ perspectives on managing overactive bladder (OAB), with a special focus on the prescribing practice of mirabegron in Indian settings. Methodology: A cross-sectional, multi-response survey was conducted among clinicians specialized in OAB management. Participants completed a 19-item questionnaire distributed via email or online platforms. The survey explored prescription practices, clinical observations, and preferences regarding mirabegron in OAB management. Data analysis involved descriptive statistics, with responses presented as frequencies and percentages. Results: More than half (58.82%) of respondents reported that patients aged 40-50 most commonly present with OAB in routine practice. The majority (88.24%) of the participants identified frequent urination, leakage, and nocturia as the prevalent symptoms in OAB patients. Approximately 65% of participants preferred mirabegron for managing OAB, and about 71% of clinicians rated mirabegron a 5 on a scale of 1-5 in terms of effectiveness for controlling OAB symptoms. Over half (58.82%) of the participants noted that mirabegron improves mean volume voided per micturition compared to antimuscarinics. Around 53% of respondents reported that dry mouth, constipation, and urinary retention are among the fewer side effects of mirabegron. All (100%) of the participants favored shifting patients from solifenacin to mirabegron when symptomatic relief was inadequate. Approximately 41% of participants preferred mirabegron for managing OAB in patients with predominant nocturia. Conclusion: The survey highlighted mirabegron as the preferred treatment for OAB, especially for patients with nocturia or inadequate relief from solifenacin. Clinicians noted its significant benefits, including better symptom control and quality of life, fewer side effects, and enhanced efficacy when combined with solifenacin, making it a valuable treatment option.